ReviewOpen heart2021
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review.
Review in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Anticoagulants for people hospitalised with COVID-19: a rapid reviewThe Cochrane database of systematic reviews · 2022Pooled it
- Incidence of Thrombotic Complications in COVID-19 Patients and the Impact of Antithrombotic Therapy on ICU Mortality.Cureus · 2025Article
- Mental Health During COVID-19: An Evaluation of Academic Universities' Contribution to Existing Research.Journal of multidisciplinary healthcare · 2024Review
- Review
- Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina.North Carolina medical journal · 2023Article
- Identifying health research in the era of COVID-19: A scoping review.SAGE open medicine · 2023Article
- COVID-19-Associated Thrombotic Complication: Is It Pulmonary Embolism or In Situ Thrombosis?Radiology research and practice · 2023Article
- Descriptive epidemiology of COVID-19 in Japan 2020: insights from a multihospital database.Annals of clinical epidemiology · 2023Article
- Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation.Frontiers in cellular and infection microbiology · 2022Review
- Observational
- Significance of MPV, RDW and PDW with the Severity and Mortality of COVID-19 and Effects of Acetylsalicylic Acid Use.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".Heart & lung : the journal of critical careArticle
Corrections and comments
- Erratum issuedCorrection:2021
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic and thromboembolic events. Therefore, understanding the effect of antiplatelet and anticoagulation therapy in the context of COVID-19 treatment is important. The aim of this rapid review was to highlight the role of thrombosis in COVID-19 and to provide new insights on the use of antithrombotic therapy in its management. A rapid systematic review was performed using preferred reporting items for systematic reviews. Papers published in English on antithrombotic agent use and COVID-19 complications were eligible. Results showed that the use of anticoagulants increased survival and reduced thromboembolic events in patients. However, despite the use of anticoagulants, patients still suffered thrombotic events likely due to heparin resistance. Data on antiplatelet use in combination with anticoagulants in the setting of COVID-19 are quite scarce. Current side effects of anticoagulation therapy emphasise the need to update treatment guidelines. In this rapid review, we address a possible modulatory role of antiplatelet and anticoagulant combination against COVID-19 pathogenesis. This combination may be an effective form of adjuvant therapy against COVID-19 infection. However, further studies are needed to elucidate potential risks and benefits associated with this combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.